美股A股
StockGist
Back
8-K2026-04-28· qwen-plus

QUCY · Mainz Biomed N.V.

0001213900-26-048635

SEC filing

Summary

Mainz Biomed B.V. completed a $6 million private placement with David Lazar, resulting in his acquisition of over 95% of voting rights, a corporate name change to Quantum Cyber N.V., issuance of new preferred share series with high conversion ratios, and a complete board refresh effective April 22, 2026.

Key takeaways

Full analysis

This filing documents a transformative control transaction that fundamentally reshapes Mainz Biomed’s corporate identity, governance, capital structure, and strategic direction. The $6 million private placement with David Lazar—structured across five distinct preferred share series—was not merely a financing event but a de facto takeover: Lazar gained over 95% of voting rights on a fully diluted basis, triggering Item 5.01 (Changes in Control). Critically, the conversion mechanics are highly asymmetric: Series A–C convert at 9:1, while Series D–E convert at 225:1—meaning the latter alone represent more than 90% of fully diluted ordinary shares post-issuance, signaling extreme dilution risk for existing shareholders and potential future equity overhang. The concurrent name change to Quantum Cyber N.V. (with ticker QUCY retained) strongly implies a pivot away from biomedicine toward cybersecurity or quantum technologies—a material strategic shift requiring investor reassessment of core competencies, market positioning, and management expertise. Governance was overhauled entirely: four long-standing directors resigned, including all three committee chairs (Audit, Compensation, Nomination), and Lazar joined a newly constituted four-person board alongside three directors with extensive public-company audit and legal experience—Natan (audit committee financial expert), Ben-Tzvi (corporate counsel), and Liscouski (security/infrastructure background). The April 22, 2026 shareholder vote ratified every element—including the name change, massive authorized share increases (to 900M ordinary and 100M preferred), and Lazar’s executive appointment—confirming broad, albeit low-turnout (38% quorum), endorsement of this restructuring. For investors, the implications are profound: loss of minority influence, exposure to untested business strategy, structural dilution pressure, and reliance on a new controlling shareholder whose prior domain expertise is not disclosed in the filing.